AU2001250412A1 - Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction - Google Patents
Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interactionInfo
- Publication number
- AU2001250412A1 AU2001250412A1 AU2001250412A AU5041201A AU2001250412A1 AU 2001250412 A1 AU2001250412 A1 AU 2001250412A1 AU 2001250412 A AU2001250412 A AU 2001250412A AU 5041201 A AU5041201 A AU 5041201A AU 2001250412 A1 AU2001250412 A1 AU 2001250412A1
- Authority
- AU
- Australia
- Prior art keywords
- chemokine receptor
- analysing
- tumour
- medicament
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10016013 | 2000-03-31 | ||
DE10016013 | 2000-03-31 | ||
PCT/EP2001/003708 WO2001072830A2 (en) | 2000-03-31 | 2001-04-02 | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001250412A1 true AU2001250412A1 (en) | 2001-10-08 |
Family
ID=7637100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001250412A Abandoned AU2001250412A1 (en) | 2000-03-31 | 2001-04-02 | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030186889A1 (en) |
EP (1) | EP1268554A2 (en) |
JP (1) | JP2003530325A (en) |
AU (1) | AU2001250412A1 (en) |
WO (1) | WO2001072830A2 (en) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0740701B1 (en) * | 1994-01-13 | 2006-12-06 | The Regents of the University of California | Mammalian monocyte chemoattractant protein receptors |
US20070072250A1 (en) * | 2002-04-08 | 2007-03-29 | Bioinfra Inc. | Method and system for analysis of cancer biomarkers using proteome image mining |
KR100383529B1 (en) * | 2002-04-08 | 2003-05-12 | Biolnfra Inc | Method and system for analysis of cancer biomarker using proteome image mining |
AU2003250221A1 (en) * | 2002-08-19 | 2004-03-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6) |
EP2359689B1 (en) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Microfluidic device for cell separation and use thereof |
CA2516138A1 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
WO2005084708A1 (en) * | 2004-03-09 | 2005-09-15 | Kyoto University | Medicinal composition containing cxcr3 inhibitor |
CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
CN102973947A (en) | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | Antibody-drug conjugates and methods |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP1698902A1 (en) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Use of XCR1 for diagnosing or monitoring of immune tolerance |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
WO2006126209A1 (en) * | 2005-05-26 | 2006-11-30 | Rappaport Family Institute For Research In The Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
EP2004675A1 (en) * | 2006-03-16 | 2008-12-24 | Protagonists Ltd. | Combination of cytokine and cytokine receptor for altering immune system functioning |
US7879799B2 (en) * | 2006-08-10 | 2011-02-01 | Institute For Systems Biology | Methods for characterizing glycoproteins and generating antibodies for same |
ES2456963T3 (en) | 2007-06-04 | 2014-04-24 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of inflammatory diseases and methods for using them |
WO2010041150A2 (en) * | 2008-10-10 | 2010-04-15 | Protagonists Ltd. | Pharmaceutical peptides for the treatment of inflammatory diseases |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
BR112012026213B1 (en) | 2010-04-15 | 2021-12-28 | Medimmune Limited | PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE |
AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
RU2609649C2 (en) | 2010-06-28 | 2017-02-02 | Универзитетсклиникум Фрайбург | Block of ccl18 signaling through ccr6 as therapeutic method of treating fibrotic diseases and cancer |
KR101862236B1 (en) | 2010-09-02 | 2018-05-29 | 백시넥스 인코포레이티드 | Anti-cxcl13 antibodies and methods of using the same |
MX343085B (en) * | 2010-11-08 | 2016-10-24 | Novartis Ag | Cxcr2 binding polypeptides. |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
MX2013013054A (en) | 2011-05-12 | 2014-02-20 | Genentech Inc | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides. |
CA2846370C (en) * | 2011-09-01 | 2019-04-23 | Eisai R&D Management Co., Ltd. | Anti-human xcr1 antibodies |
CN103987407B (en) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and conjugate thereof |
CA2865928C (en) | 2012-03-02 | 2021-02-16 | Vaccinex, Inc. | Cxcl13 antagonist for the treatment of sjogren's syndrome |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
US9718887B2 (en) | 2012-09-06 | 2017-08-01 | Adelaide Research & Innovation Pty Ltd | Methods and products for preventing and/or treating metastatic cancer |
PT2906296T (en) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
PL2906298T3 (en) | 2012-10-12 | 2019-04-30 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
ES2660029T3 (en) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Antibody-pyrrolobenzodiazepine conjugates |
NZ707490A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
CA2887894C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
ES2658888T5 (en) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
NZ710744A (en) | 2013-01-31 | 2020-07-31 | Vaccinex Inc | Methods for increasing immunoglobulin a levels |
TWI680766B (en) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
MX364330B (en) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof. |
EP3033111B1 (en) | 2013-08-12 | 2019-03-13 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
BR112016013258A2 (en) | 2013-12-16 | 2018-01-16 | Genentech Inc | antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit |
PE20161394A1 (en) | 2013-12-16 | 2017-01-06 | Genentech Inc | PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES |
JP6531166B2 (en) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | Pyrrolobenzodiazepine and its conjugate |
SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
MX2017006770A (en) | 2014-11-25 | 2018-02-09 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates. |
JP6752204B2 (en) | 2014-12-03 | 2020-09-09 | ジェネンテック, インコーポレイテッド | Quadruple amine compounds and their antibodies-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (en) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | Pyrrolobenzodiazepine prodrug and its antibody conjugate |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
DK3544636T3 (en) | 2017-02-08 | 2021-05-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine antibody conjugates |
CN110582505B (en) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | Pyrrolobenzodiazepine conjugates |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
RS62928B1 (en) | 2017-08-18 | 2022-03-31 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thailanstatin analogs |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
JP2022513198A (en) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
TW202216771A (en) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | Ccr8 antibodies for therapeutic applications |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL78444A (en) * | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
US6448379B1 (en) * | 1993-09-14 | 2002-09-10 | Chiron Corporation | IL8 inhibitors |
AU3681795A (en) * | 1994-09-23 | 1996-04-09 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
EP0939634A4 (en) * | 1996-08-15 | 2001-02-21 | Smithkline Beecham Corp | Il-8 receptor antagonists |
AU4820399A (en) * | 1998-06-29 | 2000-01-17 | Hyseq, Inc. | A chemokine receptor obtained from a cdna library of fetal liver-spleen |
-
2001
- 2001-04-02 EP EP01923710A patent/EP1268554A2/en not_active Withdrawn
- 2001-04-02 AU AU2001250412A patent/AU2001250412A1/en not_active Abandoned
- 2001-04-02 WO PCT/EP2001/003708 patent/WO2001072830A2/en not_active Application Discontinuation
- 2001-04-02 US US10/239,423 patent/US20030186889A1/en not_active Abandoned
- 2001-04-02 JP JP2001571761A patent/JP2003530325A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20030186889A1 (en) | 2003-10-02 |
WO2001072830A2 (en) | 2001-10-04 |
EP1268554A2 (en) | 2003-01-02 |
WO2001072830A3 (en) | 2002-06-20 |
JP2003530325A (en) | 2003-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001250412A1 (en) | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction | |
AU3227400A (en) | Flow cell, analyte measurement apparatus and methods related thereto | |
PL398596A1 (en) | Preparation containing human antibodies for the treatment of disorders associated with TNF-α | |
AU2003269820A1 (en) | Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods | |
WO2004022718A3 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
AU1213401A (en) | Techniques using heat flow management, stimulation, and signal analysis to treatmedical disorders | |
EP1392361A4 (en) | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 | |
AU7867600A (en) | Methods and apparatus for cell analysis | |
AU3878697A (en) | Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors | |
AU2003221173A1 (en) | Placenta-origin mesenchymal cells and medicinal use thereof | |
WO2006036737A3 (en) | Methods for identifying new drug leads and new therapeutic uses for known drugs | |
AU2003205913A1 (en) | Materials and methods relating to cancer diagnosis | |
AU2003250989A1 (en) | Method and nucleic acids for the analysis of breast cell proliferative disorders | |
WO2005069935A3 (en) | METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF | |
AU6502199A (en) | Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
AU6458400A (en) | Nucleic acid, polypeptides, assays, therapeutic methods and means | |
EP1569290A4 (en) | Catalyst for fuel cell and electrode using the same | |
AU2003281654A1 (en) | Catalyst electrode, process for producing the same, electrochemical device, and process for producing the same | |
AU2002246922A1 (en) | Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides | |
AU1138699A (en) | Dna demethylase, therapeutic and diagnostic uses thereof | |
AU2001283199A1 (en) | Methods and compositions for the diagnosis and treatment of brown adipose cell disorders | |
AU2003249263A1 (en) | Electrode for an electrochemical cell and process for making the electrode | |
AU2003220966A1 (en) | Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells | |
AU2002319080A1 (en) | Method for the diagnosis and therapy of renal cell carcinoma |